There are a number of reasons why I struggle with the term "standardization" in the RNA space, so I was glad to hear Nutcracker Therapeutics' Christian Moreno and Strand Therapeutics' Joseph Barberio tackle this topic during my colleague Erin Harris recent Live event. Check it out here!
Nutcracker Therapeutics
生物技术研究
Emeryville，California 4,086 位关注者
Nutcracker Therapeutics is developing mRNA therapeutics and a novel GMP manufacturing platform.
关于我们
Nutcracker Therapeutics is an RNA therapeutics company that has combined the power of advanced engineering with high-precision biosynthesis to deploy a complete RNA therapeutics platform. Armed with this high-tech advantage, we have developed a wholly owned pipeline of RNA therapeutic programs and established partnership initiatives with top clinical investigators at several leading institutions across the globe. With our platform’s ability to accelerate the development of life-changing RNA therapeutics, we seek to advance breakthrough RNA therapies at high velocity through all stages of development across a variety of indications. Our technology platform has the potential to significantly reduce costs and cycle times for RNA therapeutic development, with dramatic advantages in capacity scaling and point-of-care delivery over other RNA manufacturing approaches.
- 网站
-
https://www.nutcrackerx.com/
Nutcracker Therapeutics的外部链接
- 所属行业
- 生物技术研究
- 规模
- 51-200 人
- 总部
- Emeryville，California
- 类型
- 私人持股
- 创立
- 2018
地点
-
主要
获取路线
5858 Horton St
US，California，Emeryville，94608
Nutcracker Therapeutics员工
动态
-
We're thrilled to announce that we are launching new CRDMO capabilities to provide next generation biomanufacturing solutions for RNA drug developers! The services will leverage our Nutcracker? Manufacturing Unit to provide flexible solutions to scale down RNA production for personalized therapeutics or scale up for clinical trials. Learn more here: https://lnkd.in/ent6jWrY
-
-
Igor Khandros and Gad Berdugo will be in Boston at the 12th International mRNA Health Conference this week! We'd love to see you there!
-
-
We're thrilled to be in Boston for this year's PODD conference! Colin McKinlay will be giving a talk on our peptoid-based Nutshell? delivery vehicles.
-
-
Our pipeline has gotten a new look! Our therapeutic programs demonstrate the versatility of mRNA as a therapeutic and in vaccines: NTX-250, which targets the HPV infection that causes cervical cancer and dysplasia; NTX-470, which targets metastatic castration-resistant prostate cancer; and NTX-472, which targets B cell autoimmune and lymphoma diseases.
-
-
It's been a busy couple of months! Over the past quarter our team presented on the advancement of mRNA therapeutics, our Nutshell? Delivery Vehicles, our Nutcracker? Manufacturing Unit, antigen receptor design for solid tumors, and using machine learning to optimize drug design. Here's to a busy last quarter of the year!
-
-
-
-
-
+4
-
-
Ray L. will be attending the 16th Drug Discovery Strategic Summit next week in San Francisco. We'd love to see you there!
-
-
Gunasekaran (Guna) Kannan shares his thoughts on how mRNA can be used to overcome the development challenges in designing protein therapeutics. Thank you Guna and The Medicine Maker for making this article possible! Read the article here: https://lnkd.in/e4EJdnE9
-
-
We'll be at the AI in Drug Discovery Xchange in San Francisco tomorrow! Evan McCartney-Melstad will be leading a roundtable on how machine learning can be used to optimize structure-based drug design.
-
-
We're excited that Christian Moreno will be participating in a Cell & Gene panel titled: "From Bottleneck to Breakthrough: Reimagining the mRNA Therapeutics Supply Chain," tomorrow starting at 11AM ET! Tune in here: https://lnkd.in/eRtF-gFF
-